Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care
1.50 hr(s) | CME , MOC , ABIM
Specialty: Multiple Myeloma
Therapeutic Area(s): Hematology , Oncology
Release Date: June 17, 2021
Expiration Date: June 17, 2021
Location: Live Webcast
Recent changes in the multiple myeloma (MM) treatment landscape have occurred at “warp speed,” with multiple regulatory approvals making earlier breakthroughs appear modest by comparison. The validation of multiagent proteasome inhibitor and immunomodulatory platforms and the emergence of novel antibodies, cellular therapy, and targeted strategies have offered hematology-oncology professionals many more options to choose from when developing treatment plans. Modern management protocols can be individualized to achieve improved clinical outcomes across a range of treatment settings, from newly diagnosed to relapsed/refractory (including heavily pretreated) disease, as well as in transplant eligible and ineligible patients. This expert-led Seminars and Tumor Board event will make the “warp speed” changes in MM care comprehensible by focusing on the effects of newer therapeutics within specific disease settings. Each session will feature a dedicated Tumor Board component that will leverage the power of case-based learning to illustrate how professionals can apply evidence that can lead to improved patient outcomes in diverse MM patient populations and treatment settings. Don’t miss this exciting and informative event!